First World Consensus Conference on pancreas transplantation: Part II – recommendations

The First World Consensus Conference on Pancreas Transplantation provided 49 jury deliberations regarding the impact of pancreas transplantation on the treatment of diabetic patients, and 110 experts’ recommendations for the practice of pancreas transplantation. The main message from this consensus conference is that both simultaneous pancreas‐kidney transplantation (SPK) and pancreas transplantation alone can improve long‐term patient survival, and all types of pancreas transplantation dramatically improve the quality of life of recipients. Pancreas transplantation may also improve the course of chronic complications of diabetes, depending on their severity. Therefore, the advantages of pancreas transplantation appear to clearly surpass potential disadvantages. Pancreas after kidney transplantation increases the risk of mortality only in the early period after transplantation, but is associated with improved life expectancy thereafter. Additionally, preemptive SPK, when compared to SPK performed in patients undergoing dialysis, appears to be associated with improved outcomes. Time on dialysis has negative prognostic implications in SPK recipients. Increased long‐term survival, improvement in the course of diabetic complications, and amelioration of quality of life justify preferential allocation of kidney grafts to SPK recipients. Audience discussions and live voting are available online at the following URL address: http://mediaeventi.unipi.it/category/1st‐world‐consensus‐conference‐of‐pancreas‐transplantation/246.

[1]  U. Boggi,et al.  First world consensus conference on pancreas transplantation: Part I—Methods and results of literature search , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  R. Redfield,et al.  Outcomes of Pancreas Transplant Recipients With De Novo Donor-specific Antibodies. , 2019, Transplantation.

[3]  J. Cooper,et al.  De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens. , 2017, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[4]  A. Garg,et al.  Summary of Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors , 2017, Transplantation.

[5]  A. Webster,et al.  Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. , 2014, The Cochrane database of systematic reviews.

[6]  Toshinori Ito,et al.  Report from the Japan Registry of Pancreas Transplantation (2000-2012): outcomes of pancreas transplantation from marginal donors. , 2013, Clinical transplants.

[7]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[8]  H. Schrem,et al.  Pancreas transplantation with histidine-tryptophan-ketoglutarate (HTK) solution and University of Wisconsin (UW) solution: is there a difference? , 2007, JOP : Journal of the pancreas.

[9]  P. Morel,et al.  Impact of HLA matching on the outcome of simultaneous pancreas-kidney transplantation. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  L. Pączek,et al.  The comparison of treatment results of type 1 diabetes mellitus complicated by end-stage diabetic nephropathy in patients undergoing simultaneous pancreas and pre-emptive kidney transplantation (SPPkTx) and patients enrolled into the dialysis program--a cohort study. , 2005, Annals of transplantation.

[11]  R. Margreiter,et al.  Experience with ATG short course high dose induction therapy in a series of 112 enteric drained pancreatic transplants. , 2002, Annals of transplantation.

[12]  R. Merion,et al.  Randomized, prospective trial of mycophenolate mofetil versus azathioprine for prevention of acute renal allograft rejection after simultaneous kidney-pancreas transplantation. , 2000, Transplantation.

[13]  V. Papalois,et al.  Successful procurement of 50 pancreatic grafts using a simple and fast technique. , 1998, International surgery.

[14]  C. Larsen,et al.  Drainage of the exocrine pancreas in clinical transplantation: comparison of bladder versus enteric drainage in a consecutive series. , 1997, Clinical transplantation.

[15]  D. Dunn,et al.  Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. , 1996, Journal of the American College of Surgeons.

[16]  G. Barone,et al.  Prophylactic wound antibiotics for combined kidney and pancreas transplants. , 1996, Clinical transplantation.

[17]  D. Dunn,et al.  Vascular graft thrombosis after pancreatic transplantation: univariate and multivariate operative and nonoperative risk factor analysis. , 1996, Journal of the American College of Surgeons.

[18]  J. Roberts,et al.  Low postoperative wound infection rates are possible following simultaneous pancreas-kidney transplantation. , 1995, Transplantation proceedings.

[19]  A. Secchi,et al.  Evolution of carotid vascular lesions in kidney-pancreas and kidney-alone transplanted insulin-dependent diabetic patients. , 1995, Transplantation proceedings.

[20]  D. Sutherland.  Present status of pancreas transplantation alone in nonuremic diabetic patients. , 1994, Transplantation proceedings.

[21]  K. Leunissen,et al.  A positive T cell crossmatch and accelerated acute rejection of a pancreas-spleen allograft. , 1992, Transplantation.